StocksMediumUpdated×2•Originally published 5 November 2026•Updated 6 November 2026•
1 min read

Halozyme Raises FY2026 Guidance Following Record Q3 Royalty Revenue

By

Key Facts

1Halozyme achieved record ENHANZE royalty revenue of $341 million in the third quarter.
2The company raised its full-year non-GAAP EPS guidance to a range of $8.75-$9.05.
3Revenue climbed 39.1% year over year with third-quarter non-GAAP EPS reaching $2.39.

Halozyme raised its full-year 2026 non-GAAP EPS guidance to a range of $8.75 to $9.05. 24/7 Wall St. reported that the company achieved record ENHANZE technology royalty revenue of $341 million in the third quarter, driving a 39.1% year-over-year increase in total revenue. Non-GAAP EPS for the quarter reached $2.39, supported by strong commercial performance from partner products.

Royalty revenue surged 44% compared to the previous year, fueled by the market success of partnered drugs including DARZALEX SC and VYVGART Hytrulo. According to 24/7 Wall St., the company also secured a legal victory in a Dutch court protecting its patents against Merck, which blocks the launch of competing products in multiple European markets. Despite the guidance hike and record financials, Halozyme shares saw a slight decline in the minutes following the release on November 5, 2026.

Latest Updates · 2

  1. Notable·

    Update: Halozyme issued a long-term outlook stating that the final rules of the Medicare Drug Price Negotiation Program are expected to have zero to minimal impact on its royalty revenue. The company projects this revenue stability to persist through at least 2035.

  2. Notable·

    Update: Halozyme's total Q3 revenue reached $493 million, surpassing analyst estimates of $486.4 million. Non-GAAP EPS also beat expectations by 1.5%, further reinforcing the strong financial performance reported by the company on November 5, 2026.

Sources

Open on chart